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Abstract
Background: We have previously identified tissue inhibitor of metalloproteinases-1 (TIMP-1) as a prognostic marker
in glioblastomas. TIMP-1 has been associated with chemotherapy resistance, and CD63, a known TIMP-1-binding
protein, has been suggested to be responsible for this effect. The aim of this study was to assess CD63 expression
in astrocytomas focusing on the prognostic potential of CD63 alone and in combination with TIMP-1.
Methods: CD63 expression was investigated immunohistochemically in a cohort of 111 astrocytomas and
correlated to tumor grade and overall survival by semi-quantitative scoring. CD63 expression in tumor-associated
microglia/macrophages was examined by double-immunofluorescence with ionized calcium-binding adapter
molecule 1 (Iba1). The association between CD63 and TIMP-1 was investigated using previously obtained TIMP-1
data from our astrocytoma cohort. Cellular co-expression of TIMP-1 and CD63 as well as TIMP-1 and the tumor stem
cell-related markers CD133 and Sox2 was investigated with immunofluorescence. TIMP-1 and CD63 protein
interaction was detected by an oligonucleotide-based proximity ligation assay and verified using
co-immunoprecipitation.
Results: The expression of CD63 was widely distributed in astrocytomas with a significantly increased level in
glioblastomas. CD63 levels did not significantly correlate with patient survival at a protein level, and CD63 did not
augment the prognostic significance of TIMP-1. Up to 38% of the CD63+ cells expressed Iba1; however, Iba1 did
not appear to impact the prognostic value of CD63. A significant correlation was found between TIMP-1 and CD63,
and the TIMP-1 and CD63 proteins were co-expressed at the cellular level and located in close molecular proximity,
suggesting that TIMP-1 and CD63 could be co-players in glioblastomas. Some TIMP-1+ cells expressed CD133
and Sox2.
Conclusion: The present study suggests that CD63 is highly expressed in glioblastomas and that TIMP-1 and CD63
interact. CD63 does not add to the prognostic value of TIMP-1. Co-expression of TIMP-1 and stem cell markers as
well as the wide expression of CD63 might suggest a role for TIMP-1 and CD63 in glioblastoma stemness.
Keywords: TIMP, CD63, LAMP-3, Glioblastoma, Glioma, Astrocytoma, Microglia, Extracellular matrix, Prognosis,
Biomarker
Background
Glioblastomas are the most common primary brain tu-
mors in adults and among the most lethal cancers. Des-
pite aggressive treatment consisting of surgery, radiation,
and temozolomide, glioblastomas remain incurable [1].
Complete surgical resection is almost impossible to
achieve, and it is well-known that glioblastomas are
partly resistant towards therapy possibly explaining the
dismal patient prognosis. Especially, the immature
tumor-initiating cells – the supposed tumor stem-like
cells – may explain the apparent resistance towards
radio- and chemotherapy [2–5]. The mechanisms behind
this resistance are complex with multiple contributing
factors. One of these factors could be tissue inhibitor of
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metalloproteinase 1 (TIMP-1) as TIMP-1 is involved in
different cellular survival functions [6–8] and has been
associated with decreased chemo-sensitivity in breast
and colorectal cancer [9–13].
Using immunohistochemistry we have previously
shown that TIMP-1 levels increase with World Health
Organisation (WHO) malignancy grade in patients with
astrocytoma, and that low levels of TIMP-1 predict a
significantly longer overall survival compared with
moderate or high TIMP-1 levels in patients with glio-
blastoma [14]. Similarly, high TIMP-1 levels were re-
ported to correlate with poor prognosis in colorectal
[15–18], breast [19–23], gastric [24, 25], and ovarian
cancer [26, 27].
Jung et al. showed that TIMP-1 interacts with the cell
surface protein CD63, also known as Lysosomal Associ-
ated Membrane Protein 3 (LAMP-3), and integrin β1 on
the surface of the breast cell line MCF10, which prevented
chemo-induced apoptosis [28] suggesting that interaction
between TIMP-1 and CD63 may contribute to chemo-
resistance. CD63 is a tetraspanin that interacts with vari-
ous proteins such as integrins and tyrosine kinases in-
volved in regulation of intracellular signal transduction
pathways controlling cell adhesion, motility, and survival
[28–31]. The CD63 protein is also enriched in exosomes
[32]. Reportedly, exosomes contribute significantly to the
intercellular communication also in gliomas [32–35] and
may play a role in chemo-resistance in cancer [35, 36].
Only few studies have investigated the presence of CD63
in gliomas [37, 38]. Using tissue microarrays, Rorive et al.
found the highest level of CD63 expression in pilocytic as-
trocytomas followed by glioblastomas and anaplastic as-
trocytomas with the lowest expression in diffuse
astrocytomas [37]. Further, CD63 was found to interact
with TIMP-4, and CD63/TIMP-4 co-expression was associ-
ated with poorer outcome in glioblastoma patients. In con-
trast, Kase et al. found high amounts of CD63+ immune
cells was correlated with better survival following postoper-
ative radiotherapy in patients with glioblastoma [38].
Whether TIMP-1 and CD63 can interact on the sur-
face of glioblastoma cells is so far unknown. A study by
Lee et al. showed that glioma-derived TIMP-1 can pro-
mote migration of neural stem cells towards the tumor
by interacting with CD63 expressed by the stem cells.
Similar results were reported for CD34+ hematopoietic
stem and progenitor cells (HSPCs), where CD63 to-
gether with integrin β1was identified as a receptor com-
plex for TIMP-1 mediating cellular adhesion and
migration [39] as well as clonogenic expansion and sur-
vival in HSPCs [40]. Collectively, these results suggest a
close co-operation between TIMP-1 and CD63 [41].
The aim of this study was to assess the prognostic im-
pact of CD63 alone and in combination with TIMP-1 by
performing immunohistochemistry on a cohort of 111
astrocytomas, described and used previously for evalu-
ation of the prognostic potential of TIMP-1 [14]. Co-
expression patterns of TIMP-1 and CD63 were investi-
gated using double-immunofluorescence, proximity
ligation assay, and co- immunoprecipitation. The possible
co-expression of CD63 and the microglial/macrophage
marker ionized calcium-binding adapter-molecule 1 (Iba1)
was examined using double-immunofluorescence. To in-
vestigate the association between TIMP-1 and cancer
stemness, double-immunofluorescence stainings were per-
formed using sex determining region Y-box 2 (Sox2) [42,
43] and CD133 [5, 44–47] as markers of tumor stem-like
cells.
Methods
Patient tissue
The immunohistochemical expression of CD63 was
assessed in archive tumor material obtained from 111
patients who underwent initial surgery for primary gli-
oma between 1995 and 2005 at Odense University Hos-
pital, Denmark. None of the patients had received
treatment prior to craniotomy. The patient cohort has
been described in previous studies [14, 44, 48, 49]. All
tumors were re-classified according the 2016 World
Health Classification (WHO) [1]. The cohort included
23 diffuse astrocytomas, 14 anaplastic astrocytomas, and
74 glioblastomas. Patient characteristics are described in
Table 1.
Table 1 Patient characteristics
Diffuse astrocytoma Anaplastic astrocytoma Glioblastoma
Patients (n) 23 14 74
Age
Mean 45.0 52.2 61.4
Range 2.6–78.5 29.9–77.3 21.2–78.4
Sex (n)
Male 15 8 48
Female 8 6 26
Status (n)
Alive 4 0 1
Dead 19 14 73
Over survival (months)
Median 57.1 18.4 8.4
Range 3.4–267.0 2.1–48.3 0.08–163.5
IDH statusa
Mutated 14 4 2
Wildtype 9 10 72
aIDH status was only investigated by immunohistochemistry for glioblastoma
patients. For patients diagnosed with diffuse and anaplastic astrocytoma, IDH
status was investigated by immunohistochemistry and next generation
sequencing (See Materials and Methods section: Immunohistochemistry)
Abbreviations: IDH isocitrate dehydrogenase
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In vitro culturing of spheroids
In vitro culturing of five different patient-derived spher-
oids was performed using fresh tumor tissue from five
patients who underwent initial surgery for astrocytoma
WHO grade III and IV from September 2007 through
May 2008 at the Department of Neurosurgery, Odense
University Hospital, Denmark. Written informed con-
sent was obtained from all five patients. The tumor tis-
sue was processed and cultured as described earlier [50].
In brief, tumor tissue was sectioned manually into
small fragments of 200–400 μm using two scalpels.
The tumor fragments were cultured for 10–15 days
in 0.75% agar-coated culture flasks of 75 cm2 contain-
ing 20 mL Dulbeccos Modified Eagle Medium (Sigma
Aldrich, USA) supplemented with 10% fetal calf
serum (Fisher Scientific, USA), 2% glutamine (Cam-
brex, USA), 4% nonessential amino acids (Cambrex),
and 2% penicillin/streptomycin (Cambrex) until spher-
oids were formed in a standard tissue culture incuba-
tor (95% humidity, 95% air, and 5% CO2).
Commercial U87MG cell line-derived spheroids were
cultured under the same conditions until reaching a
size of 200–400 μm. Spheroids were then fixed in 4%
neutral buffered formaldehyde for 24 h and embedded
in paraffin. Afterwards, the preservation and expres-
sion patterns of TIMP-1, CD63, and the stem-related
markers CD133 and Sox2 were investigated by im-
munofluorescence and confocal microscopy.
Immunohistochemistry
Formaldehyde-fixed, paraffin-embedded tissue was cut into
three μm sections on a microtome and stained routinely
with haematoxylin-eosin to define representative tumor re-
gions. For immunohistochemical staining with CD63, par-
affin sections were then deparaffinized, and endogenous
peroxidase activity was quenched followed by heat-induced
epitope retrieval (HIER) in TRS buffer (Dako, Denmark).
The sections were subsequently incubated for 60 min with
a CD63 monoclonal antibody (MX-49.129.5, Santa Cruz, 1
+ 1000, USA). The antigen-antibody complex was detected
using anti-mouse EnVision (Dako) and visualised with di-
aminobenzidine (DAB) as chromogen. Finally, the sections
were counterstained with Mayer’s haematoxylin.
Immunohistochemical staining for mutation in iso-
citrate dehydrogenase 1 (IDH-1) was performed as
previously described [51, 52]. For diffuse and anaplas-
tic astrocytomas that were IDH-1 wildtype by immu-
nohistochemistry, next generation sequencing was
performed using the 20-gene panel as reported by
Zacher et al. [53].
Scoring of the CD63 staining
The immunohistochemical scores were based on the
average percentage of CD63+ tumor cells, CD63+ tumor
blood vessels as well as the overall staining intensity for
both tumor cells and blood vessels (Table 2). Necrotic
areas as well as invasion zones were excluded. To obtain
a total CD63 score for each patient, the scores for stain-
ing positivity and intensity of both tumor cells and blood
vessels were summed resulting in a maximum total
CD63 score of 12. For comparison with overall patient
survival, the tumors were divided into three groups cor-
responding to a low (total CD63 scores 0–6), medium
(total CD63 scores 7–8), and high (total CD63 scores 9–
12) CD63 expression. The scoring system and the scor-
ing process were developed and was carried out under
the supervision of an experienced neuropathologist.
Immunofluorescence and automated quantitative image
analysis
To investigate the expression of CD63 in immune cells,
double-immunofluorescence was performed on archive
tumor material from ten glioblastoma patients. The
preparations and the first steps in the stainings are as
described above. Following detection of CD63 (NK1/C3,
1 + 50, Abcam, United Kingdom) using Catalyzed Signal
Amplification (CSA) II kit with fluorescein (Dako), sec-
tions were incubated with an antibody against Iba1
(019–19,741, 1 + 12,000, Wako Pure Chemical Indus-
tries, Japan) followed by detection with Tyramide Ampli-
fication Signal (TSA)-Cyanine-5 (Perkin Elmer, USA).
Nuclei were counterstained with 4.6-diamidino-2-pheny-
lindole (DAPI) (VWR International, USA). Image acqui-
sition and analysis were performed using a Visiopharm
integrated Leica DM6000B microscope and software mod-
ule (Visiopharm, Denmark) connected to an Olympus
DP72 1.4 Mega Pixel CCD camera (Olympus, Japan) using
DAPI (Omega XF06, Omega Optical, USA), fluorescein
(Leica, Germany), and Cyanine-5 (Omega XF110–2) fil-
ters. Overview images were acquired using bright field set-
tings. Sampling regions containing vital tumor tissue was
manually outlined, and sample images were taken with a
20× objective. Images were quantified using a threshold-
based algorithm developed in the Visiopharm software de-
fining the total nuclear area using the DAPI signal. Nuclei
surrounded by the Iba1 and/or the CD63 signal were then
identified as positive or double-positive cells. Area frac-
tions were then measured calculating the area of double-
positive cells as fractions of the total Iba1+ cell area or of
the total CD63+ cell area.
Immunofluorescence and confocal microscopy
HIER was performed in TEG buffer (10 mmol/L Tris-
base and 0.5 mmol/L EGTA) followed by incubation for
60 min with a TIMP-1 (VT7 [54], 1 + 4000) or a CD133
(W6B3C1, 1 + 40, Miltenyi, Belgium) antibody. The pri-
mary antibody was detected using the CSA II kit (Dako)
(TIMP-1 and CD133) or TSA Plus System (Perkin
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Elmer) (TIMP-1). HIER was repeated followed by incu-
bation for 60 min with an antibody against Sox2
(245,610, 1 + 800, R&D Systems, USA), CD63 (MX-
49.129.5, 1 + 800, Santa Cruz), or TIMP-1 (VT7, 1 +
4000). A secondary antibody with Alexa488 (Invitrogen,
USA) was used for Sox2, whereas TSA (Perkin Elmer)
was used for TIMP-1 and CD63. Nuclei were counter-
stained with DAPI. The double-immunofluorescence
stainings were analysed using a Nikon Eclipse TE2000-E
inverted confocal microscope.
Proximity ligation assay
Detection of TIMP-1 and CD63 protein interaction
was investigated using Duolink In Situ (OLINK Bio-
science, Sweden) according to manufacturer’s instruc-
tions. Paraffin sections were deparaffinized, and
endogenous peroxidise activity was quenched followed
by HIER in 10 mM citrate buffer (pH 6). Next, sec-
tions were incubated with a monoclonal mouse
TIMP-1 antibody (VT7 clone [54]) and a polyclonal
rabbit CD63 antibody (HPA010088, Atlas Antibodies,
Sweden) for 60 min. Secondary antibodies conjugated
with oligonucleotides (proximity ligation assay probes)
were added, and the sections were incubated for an-
other 60 min at 37 °C. A solution containing ligase
oligonucleotides was added for 15 min at 37 °C to
bind and ligate the probes together in a closed circle.
Ligation would only occur if the probes were located
in close proximity. Finally, amplification solution was
added for 90 min at 37 °C to amplify the closed li-
gated circle, leaving a distinct fluorescent spot. Cover-
slips were mounted using DAPI to visualize cell
nuclei. Omission of primary antibodies was used as
negative control.
Immunoprecipitation
For CD63 immunoprecipitation, U87MG cell line-
derived spheroids were cultured as described above until
reaching a size of 200–400 μm. Cells were washed twice
with ice-cold PBS and lysed with lysis buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 1 mM EDTA) containing phosphatase and prote-
ase inhibitor mixtures (Roche Applied Science,
Germany). Lysates were precleared for 2 h with Protein
G-Dynabeads (Invitrogen) and then incubated overnight
with CD63 antibody (clone MX-49.129.5, Santa Cruz) or
isotype control prebound to Protein G-Dynabeads. The
resin was then washed three times with ice-cold lysis
buffer, resuspended in 30 μl of Laemmli sample buffer,
boiled for 3 min and centrifuged at 14,000 g for 5 min.
The supernatants were analysed by immunoblotting
under standard conditions.
The cancer genome atlas (TCGA) research network
The messenger RNA (mRNA) expression levels of
CD63, Iba1 (also known as allograft inflammatory fac-
tor 1 (AIF1)), and TIMP-1 were examined in astrocy-
tomas using GlioVis (http://gliovis.bioinfo.cnio.es) [55,
56]. Data were accessible for 327 patients for analysis
of the correlation between CD63 and malignancy
grade [55]. For survival analyses, data were available
for 497 glioblastoma patients [56]. Survival analyses
were performed using the median or the 25th per-
centile as cutoff values.
Differential expression analysis was done using the
TCGA to visualize quantitative changes in mRNA ex-
pression levels of 12,700 genes between the group of
glioblastomas with the highest mRNA level of CD63
(n = 123) and the group of glioblastomas with the
lowest level (n = 125). Gene Ontology (GO) term en-
richment analysis was performed for the differentially
upregulated and differentially downregulated genes
using the AmiGO 2 Term Enrichment Service (http://
amigo.geneontology.org/amigo, accessed September
30, 2017) powered by PANTHER (GO Ontology data-
base, Released 2017–09-26) [57–59].
Statistical analysis
ANOVA with Bonferroni correction was used for com-
parison of CD63 scores with tumor grade. Student’s un-
paired t-test was used to compare differences in CD63
levels in IDH wildtype and IDH mutated tumors. Overall
survival was defined from the day of initial surgery until
death or date of censoring (1 August 2017). Survival data
were analyzed using Kaplan Meier and the multivariate
Cox regression model to adjust for age, sex, and TIMP-1
scores. Survival curves were compared using the log-
rank test. Spearman’s correlation was used to investigate
Table 2 Assessment of CD63 immunohistochemical staining
Score 0 1 2 3
Positive tumor cells 0% to < 2% 2% to < 30% 30% to < 65% 65% to 100%
Tumor cell intensity None Faint Moderate Intense
Positive blood vessels 0% to < 2% 2% to < 30% 30% to < 65% 65% to 100%
Blood vessel intensity None Faint Moderate Intense
All scores were summed into a total CD63 score with maximum score of 12. Based on the total CD63 score, patients were grouped into three categories: 0–6
(low), 7–8 (medium), and 9–12 (high)
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the association between CD63 and Iba1 and between
CD63 and TIMP-1. The statistical analyses were per-
formed in STATA (StataCorp LP, USA) or GraphPad
Prism 5.0 (GraphPad Software Inc., USA). P < 0.05 was
considered significant.
Results
CD63 expression in diffuse astrocytomas
In diffuse astrocytomas with a gemistocytic pattern,
tumor cells with distinct CD63 expression were observed
(Fig. 1a), whereas a more diffuse CD63 staining was seen
in tumors with a predominantly fibrillary pattern (Fig.
1b). Tumor blood vessels also expressed CD63, although
not always adjacent to CD63+ tumor cells (Fig. 1b, c). In
some of the blood vessels, CD63 was faintly expressed
and mainly detected close to the lumen of the tumor
blood vessels corresponding to the supposed localization
of the apical endothelial membrane (Fig. 1c). An in-
creased diffuse perivascular CD63 staining was observed
in some of the fibrillary tumors (Fig. 1d); however, this
did not appear to be related to CD63 labeling of the
blood vessels.
CD63 expression in anaplastic astrocytomas and
glioblastomas
In anaplastic astrocytomas and glioblastomas, the ex-
pression patterns of CD63 appeared similar, however,
perinecrotic areas and proliferative blood vessels only
expressed CD63 in glioblastomas. In all tumors, tumor
cells showed a distinct punctate cytoplasmic CD63
expression (Fig. 2a). CD63 was detected in both fusiform
and stellate shaped tumor cells as well as in multinucle-
ated giant cells. In some areas, tumor cells also had a
distinct labeling of the plasma membrane (Fig. 2b);
while a more diffuse staining was found in other bi-
opsies (Fig. 2c). CD63+ blood vessels were often lo-
cated in relation to CD63+ tumor cells (Fig. 2c).
Mostly, blood vessels stained weakly for CD63 (Fig.
2c-d). Similar to the diffuse astrocytomas, CD63 ap-
peared to be located in the apical endothelial mem-
brane as well as in the cytoplasm of endothelial cells.
Also in some perivascular areas, tumor cells showed
an intense CD63 expression (Fig. 2d). An intense
CD63 expression was observed in pseudopalisade for-
mations (Fig. 2e), while larger necrotic areas with cel-
lular debris had a weaker and more diffuse CD63
expression (not shown). In some of the tumors, per-
ipheral tumor areas were present, and these zones
contained few diffusely invading and weakly CD63+
putative tumor cells as well as CD63+ pyramidal
shaped neurons (Fig. 2f ). Moreover, CD63+ blood
vessels were also observed in the tumor periphery.
CD63 expression levels in astrocytomas
For the percentage of CD63+ tumor cells (Fig. 3a), tumor
cell intensity (Fig. 3b), the percentage of CD63+ blood
vessels (Fig. 3c), and CD63 blood vessel intensity (Fig. 3d),
the highest scores 2 and 3 were most frequently given to
glioblastomas, whereas the lowest score 1 was most often
given to diffuse and anaplastic astrocytomas (Fig. 3a-d).
Fig. 1 Immunohistochemical expression of CD63 in diffuse astrocytomas. a Gemistocytic tumors showed distinct CD63 expression (arrows),
b whereas a more diffuse CD63 staining was seen in tumors with a fibrillary pattern. b, c A faint CD63 expression was detected close to the
lumen of the some tumor blood vessels (arrows). d In some of the fibrillary tumors, an increased diffuse perivascular staining was observed
(arrows). Scale bar: 30 μm (a, c), 100 μm (b), and 50 μm (d)
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Fig. 2 Immunohistochemical expression of CD63 in glioblastomaa A distinct cytoplasmic CD63 staining was seen in all tumors (arrow). b A
distinct plasma membrane labeling was seen in some biopsies (arrows). c, d In general blood vessels showed a weak CD63 expression, but a
more intense expression was found in perivascular tumor cells (d). e Pseudopalisade formations showed an intense CD63 expression. f A few
CD63 tumor cells with faint CD63 expression as well as CD63+ pyramidal shaped neurons (arrow) were seen in the tumor periphery. Scale bar:
50 μm (a-d) and 100 μm (e-f)
Fig. 3 Expression levels of CD63 in astrocytomasBased on the CD63 expression, the astrocytomas received a score between 0 and 3 in four
categories. Distributions are shown as percentage of the total number of tumors for the respective astrocytoma subtype for: a CD63+ tumor cells,
b tumor cell intensity, c CD63+ blood vessels, d CD63 blood vessel staining intensity, and e total CD63 score. Comparison of the mean scores
among the different WHO grades for: f CD63+ tumor cells, g tumor cell intensity, h CD63+ blood vessels, i CD63 blood vessel intensity, and j the
total CD63 score. Data are shown as mean scores + standard error of the mean (SEM). **: p < 0.01; ***: p < 0.001. Abbreviations: AA anaplastic
astrocytoma; DA diffuse astrocytoma; GBM glioblastoma
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However, very few tumors displayed clearly negative stain-
ing characteristics (Fig. 3a-d). In diffuse astrocytomas,
CD63 was expressed by the tumor cells and the tumor
blood vessels in 91% and 92% of the tumors, respectively.
CD63+ tumor cells were present in all anaplastic as-
trocytoma and glioblastoma samples, while CD63+
blood vessels were detected in 93% of the anaplastic
astrocytomas and 99% of the glioblastomas. Looking
at the total CD63 score, 74% and 71% of the diffuse
and anaplastic astrocytomas were in the lowest CD63
expression group, while this was only the case for
55% of the glioblastomas (Fig. 3e).
The amount of CD63+ tumor cells was similar in dif-
fuse and anaplastic astrocytomas, while the amount was
significantly higher in glioblastomas (p < 0.001) (Fig. 3f ).
CD63 tumor cell intensity also increased significantly
with tumor grade (p < 0.01 and p < 0.001, respectively)
(Fig. 3g). The level of CD63+ blood vessels tended to be
lowest in anaplastic astrocytomas followed by diffuse as-
trocytomas, while glioblastomas had the highest score
(p < 0.001 and p < 0.01, respectively) (Fig. 3h). The CD63
blood vessel intensity was similar for all grades (p = 1.00)
(Fig. 3i). Comparing the total CD63 score, glioblastomas
had significantly higher score compared to diffuse and
anaplastic astrocytomas (p < 0.001) (Fig. 3j). When inves-
tigating the correlation between CD63 expression and
IDH status, the level of CD63 tended to be higher in IDH
wildtype tumors, but this was not significant (Additional
file 1: Figure S1).
The prognostic potential of CD63 in astrocytomas
When investigating the association between overall sur-
vival and CD63+ tumor cell score, no significant correl-
ation was found for patients with diffuse astrocytoma (p
= 0.85), anaplastic astrocytomas (p = 0.31), or glioblast-
oma (p = 0.59). Similar results were found when examin-
ing the correlation between overall survival and tumor
cell staining intensity (diffuse astrocytoma: p = 0.25; ana-
plastic astrocytoma: p = 0.24; glioblastoma: p = 0.88),
CD63+ tumor blood vessel score (diffuse astrocytoma: p
= 0.93; anaplastic astrocytoma: p = 0.74; glioblastoma: p
= 0.27), as well as tumor blood vessel staining intensity
(diffuse astrocytoma: p = 0.96; anaplastic astrocytoma: p
= 0.74; glioblastoma: p = 0.73). Furthermore, no signifi-
cant association between the total CD63 score and over-
all survival was detected in patients with diffuse (p =
0.11) or anaplastic (p = 0.19) astrocytoma. In glioblast-
oma, patients with the lowest CD63 expression (score
0–6; n = 22) tended to have a significantly longer overall
survival than the patients with the highest CD63 expres-
sion (score 9–12; n = 23) (HR 1.61; 95% CI 0.88–2.96; p
= 0.12), and similar tendency was found when adjusting
for age and sex (HR 1.72; 95% CI 0.91–3.25; p = 0.095).
No significant difference was found between the patients
with low expression and the patients with medium ex-
pression (score 7–8; n = 29) in the univariate (HR 1.22;
95% CI 0.70–2.16; p = 0.48) or multivariate analysis (HR
1.20; 95% CI 0.68–2.14; p = 0.53) (Fig. 4a).
To further examine the impact of CD63 in astrocyto-
mas, we used TCGA datasets. We found a grade-
dependent increase in CD63 expression with glioblast-
omas having significantly higher levels compared to dif-
fuse and anaplastic astrocytomas (p < 0.001) (Fig. 4b);
also IDH wildtype tumors had significantly higher CD63
levels compared IDH mutated tumors (Additional file 1:
Figure S1). At the median mRNA expression level, high
CD63 was not significantly associated with shorter over-
all survival in patients with glioblastoma (HR 1.15; 95%
CI 0.95–1.39; p = 0.15) (data not shown). However, di-
chotomized at the 25th percentile (i.e. the 25% patients
with the lowest levels vs the 75% patients with the highest
levels), patients with low CD63 mRNA levels had signifi-
cantly better prognosis than patients with high levels (HR
1.37; CI 1.09–1.72; p = 0.007) (Fig. 4c). However, when
adjusting for age and sex, this impact was not statistically
significant (HR 1.20; 95% CI 0.95–1.51; p = 0.12).
To investigate the association between CD63 and im-
mune cells, we performed automated quantitative
double-immunofluorescence on ten glioblastomas (Fig.
4d-g). We found that the average fractions of double-
positive cells were 0.12 of the total Iba1+ cells and 0.38
of the total CD63+ cells (Fig. 4h), and analysis showed a
positive, yet insignificant, correlation between Iba1 and
CD63 expression (Spearman’s ρ = 0.55; p = 0.098). In the
TCGA dataset, a weak positive, but significant, correl-
ation was found between Iba1 and CD63 mRNA levels
(Spearman’s ρ = 0.19; p < 0.001). To examine the influ-
ence of Iba1 on the prognostic impact of CD63 in glio-
blastomas, patients included in the TCGA dataset were
dichotomized based on the median mRNA levels of Iba1
and 25th percentile level of CD63 resulting in four
groups: 1) CD63low/Iba1low, 2) CD63low/Iba1high, 3)
CD63high/Iba1low, and 4) CD63high/Iba1high (Fig. 4i). We
found that patients with CD63low/Iba1low mRNA levels
tended to have longer overall survival compared to pa-
tients with CD63high/Iba1high mRNA levels (HR 1.31;
95% CI 0.99–1.73; p = 0.059). However, no significant
differences were found between the CD63low/Iba1low and
CD63low/Iba1high groups (HR 0.83; 95% 0.53–1.28; p =
0.39) or between the CD63high/Iba1low and CD63high/
Iba1high groups (HR 1.05; 95% 0.85–1.32; p = 0.64) sug-
gesting that Iba1 levels do not impact the prognostic
value of CD63 itself.
The prognostic potential of CD63 and TIMP-1
Comparing the CD63 staining to the TIMP-1 staining,
obtained in our previous study using the same cohort
[14], the expression of CD63 and TIMP-1 appeared to
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show same grade-dependent increase (Fig. 5a-i). When
performing Spearman’s correlation analysis, we found a
weak, but significant, correlation between the total CD63
score and the total TIMP-1 score (Spearman’s ρ = 0.27;
p = 0.024). Adding the TIMP-1 score as a variable in the
regression model showed that CD63 expression did
not impact the prognostic value of TIMP-1 (Table 3).
Using the TCGA dataset, Spearman’s correlation ana-
lysis showed that CD63 mRNA levels were positively
correlated with TIMP-1 mRNA levels (Spearman’s ρ =
0.60; p < 0.001). Investigating the association between
survival and TIMP-1, we found that the 25% patients
with the lowest TIMP-1 levels had significantly longer
survival compare to the 75% with the highest levels
(HR 1.56; 95% 1.23–1.97; p < 0.001) (Fig. 5j). This
remained significant when adjusting for age and sex
(HR 1.37; 95% CI 1.08–1.73; p = 0.008). Adjusting for
both TIMP-1 and CD63 in the multivariate analysis
showed that CD63 levels did not augment the prog-
nostic value of TIMP-1 (HR 1.35; 95% CI 1.03–1.77;
p = 0.027).
Interaction between TIMP-1 and CD63
The proximity ligation assay showed TIMP-1 and CD63
proteins in close molecular proximity revealing these
interacting molecules as red spots in the tumor cells of
the glioblastoma biopsies (Fig. 5k). The same pattern was
detected in the organotypic spheroids and in U87MG
cell line-derived spheroids (not shown). To confirm this
association, CD63 immunoprecipitation was performed
with U87MG cell line-derived spheroids. Western blot-
ting of isolated immunocomplexes from these cells,
showed that anti-CD63 antibody co-immunoprecipitated
CD63 together with TIMP-1, whereas the corresponding
mouse isotype control IgG did not (Fig. 5l), indicating
that TIMP-1 is associated with CD63 under the
Fig. 4 Association between CD63, Iba1, and prognosis in glioblastomas. a Kaplan-Meier curve for glioblastoma patients stratified into
three groups based on total CD63 score. b Association between WHO malignancy grade and CD63 mRNA expression levels in the TCGA. c Using the TCGA
dataset, low CD63 levels were significantly associated with improved survival in glioblastoma patients when dichotomized at the 25th percentile.
d-f Double-immunofluorescence staining with CD63 (green) and Iba1 (red) using DAPI as nuclear staining (blue). g Software-based classification
was performed using a threshold-based algorithm. Cells were assigned color labels based on their expression of CD63 and Iba1. Cells co-expressing CD63
and Iba1 are illustrated as white-labeled nuclei, cells only expressing Iba1 are depicted as red-labeled nuclei, cells only expressing CD63 are depicted as
green-labeled nuclei, while negative cells are depicted as blue-labeled nuclei. h The areas of double-positive nuclei were calculated as fractions of the total
Iba1+ nuclear area and the total CD63+ nuclear area. i Kaplan-Meier curve for glioblastoma patients included in the TCGA dataset stratified into four groups
based on the CD63 and Iba1 mRNA expression levels. Scale bar: 100 μm. ***: p< 0.001. Abbreviations: AA anaplastic astrocytoma; DA diffuse astrocytoma;
GBM glioblastoma
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conditions of the assay. In summary, these assays sug-
gest that TIMP-1 and CD63 are located closely together
and interact in glioblastomas.
TIMP-1 and CD63/CD133/Sox2 co-expression
TIMP-1/CD63 co-expression was detected in tumor biop-
sies (Fig. 6a) as well as in the organotypic (Fig. 6b) and
U87MG cell line-derived spheroids (Fig. 6c). CD63 was
widely expressed, while TIMP-1 expression was more
infrequent, however, most TIMP-1+ cells were found to
express CD63.
Some TIMP-1/CD133 co-expressing cells were de-
tected in some of the tumor biopsies (Fig. 6d), in the
corresponding organotypic spheroids (Fig. 6e) and in the
Fig. 5 Association between TIMP-1 and CD63. a-c Representative haematoxylin-eosin, CD63, and TIMP-1 staining of a diffuse astrocytoma (DA).
d-f Representative haematoxylin-eosin, CD63, and TIMP-1 staining of an anaplastic astrocytoma (AA). g-i Representative haematoxylin-eosin, CD63,
and TIMP-1 staining of a glioblastoma (GBM). j Using the TCGA dataset, low TIMP-1 levels were significantly associated with improved survival in
glioblastoma patients when dichotomized at the 25th percentile. k Proximity ligation assay performed on glioblastoma biopsies visualizing TIMP-1
and CD63 proteins in close molecular proximity. A red dot appears when proteins are located sufficiently close together. The nuclei were visualized with
DAPI (blue color). l Immunoblotting using an anti-TIMP-1 antibody showing TIMP-1 and CD63 binding in U87MG cell line-derived spheroids. Cell
lysates were immunoprecipitated with an anti-CD63 (lane 2) and the corresponding IgG isotype as control (lane 1). Scale bar 50 μm. Asterisks
indicate blood vessels
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U87MG cell line-derived spheroids (Fig. 6f ), although
the majority of the CD133+ cells did not co-express
TIMP-1. Similar to this, TIMP-1/Sox2 co-expressing
cells were detected in some of the tumor biopsies (Fig.
6g) and in the corresponding organotypic spheroids (Fig.
6h), although the majority of the Sox2+ cells did not co-
express TIMP-1. No Sox2 expression was detected in
the U87MG cell line (Fig. 6i). CD63 was distributed in
virtually all tumor cells and spheroids and therefore,
CD63 co-expression with stem cell markers was not spe-
cifically investigated.
Differential expression analysis
To investigate the potential functional relevance of
CD63 in glioblastoma, a volcano plot was generated
using the TCGA dataset to visualize quantitative changes
in mRNA expression levels of 12,700 genes between the
groups of glioblastomas with the highest and lowest
CD63 mRNA level (Fig. 7). A total of 50 genes were dif-
ferentially upregulated (fold change > 1.50) including
chitinase-3-like protein 1 (CHI3L1/YKL-40), TIMP-1,
podoplanin (PDPN), fatty acid binding protein 7
(FAPB7), epithelial membrane protein 3 (EMP3), pentra-
xin 3 (PTX3), and periostin (POSTN), while 32 genes
were downregulated (fold change > − 1.50); among these
were delta-like 3 (DLL3), lipid phosphate phosphatase-
related protein type 1 (LPPR1), and doublecortin (DCX)
(Fig. 7a and Additional file 2: Table S1). GO term
enrichment analysis was used to retrieve a biological pro-
file of the differentially regulated genes; upregulated genes
appeared to be involved in cell activation, regener-
ation, regulation of cell death, migration, and immune re-
sponse (Fig, 7b), whereas downregulated genes appeared
to be involved in cell differentiation and development, es-
pecially in the central nervous system (Fig. 7c).
Discussion
In a previous study, we showed that TIMP-1 was a sig-
nificant prognostic marker in glioblastomas, and in the
present study we aimed to further investigate the role of
TIMP-1 in glioblastomas by focusing on the potential
TIMP-1 interacting protein CD63. We showed that the
immunohistochemical expression of CD63 was highest
in glioblastomas, but CD63 was not significantly associ-
ated with overall survival alone or in combination with
TIMP-1, however, high levels tended to correlate with
poorer prognosis. The TIMP-1 and CD63 proteins ap-
peared to be located in close molecular proximity sug-
gesting TIMP-1/CD63 interaction. This possible
interaction has to our knowledge not been shown before
in glioblastomas.
CD63 has previously been associated with cancer; how-
ever, the expression pattern differs dependent on the spe-
cific cancer type. In melanomas, high CD63 protein levels
were associated with early stages of tumor progression
and low levels with late disease stages [60], while CD63
mRNA expression levels were similar in pancreatic cancer
and normal pancreatic tissue [61]. In lung adenocarcin-
omas, low CD63 levels relative to normal lung tissue were
significantly associated with poorer survival for patients
with grade I and II disease, but not for grade III [62]. In
contrast, Kanao et al. showed that high CD63 mRNA ex-
pression was associated with a poor overall survival for
stage I and II uterine cervical cancers [63].
In the present study, the immunohistochemical ex-
pression of CD63 protein was assessed in the same pa-
tient cohort that we previously used to examine TIMP-1
Table 3 Multivariate analysis of total CD63 score and total TIMP-1 score
Baseline model CD63
Patients (n) HR (95% CI) P-value HR (95% CI) P-value
Age (continuous) 74 1.01 (0.98–1.03) 0.70 1.00 (0.98–1.03) 0.71
Sex
Male 47 1.00 1.00
Female 27 0.82 (0.49–1.37) 0.44 0.76 (0.45–1.29) 0.31
TIMP-1 score
0–5 12 1.00 1.00
6–7 26 5.05 (2.14–11.9) < 0.001 5.06 (2.13–12.0) < 0.001
8–9 24 3.33 (1.43–7.71) 0.005 3.27 (1.38–7.76) 0.007
10–12 12 5.18 (1.96–13.6) 0.001 4.66 (1.74–12.5) 0.002
CD63 score
0–6 22 – – 1.00
7–8 29 – – 1.09 (0.58–2.06) 0.79
9–12 23 – – 1.51 (0.78–2.91) 0.22
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protein expression (14). We detected CD63+ tumor cells
in the majority of the tumors and found a significantly
higher CD63 expression in glioblastomas compared to
diffuse and anaplastic astrocytomas. In contrast to the
considerable variation observed in the TIMP-1 expres-
sion in glioblastomas [14], the variation in the CD63 ex-
pression was minor, and virtually all tumor cells were
positive. The homogeneous CD63 expression in the bi-
opsies partly explains the low correlation between
TIMP-1 and CD63 observed in the present study. CD63
was also expressed in tumor blood vessels as well as in
neurons in the tumor periphery. This may suggest that
CD63 is important for tumor cell biology as well as for
angiogenesis and neuronal survival.
Only few studies describe the presence of CD63 pro-
tein in gliomas using immunohistochemistry [37, 38].
Rorive et al. investigated the expression of CD63 on ten
tissue microarrays consisting of 471 gliomas and found
the CD63 expression to increase significantly with astro-
cytoma grade being significantly highest in glioblastomas
and anaplastic astrocytomas compared to diffuse astro-
cytoma. In contrast, we found the highest CD63 expression
in glioblastomas, but no difference was observed be-
tween anaplastic and diffuse astrocytomas. This discrep-
ancy may be explained by a difference in the number of
tumors with IDH mutation. Rorive et al. did not report
IDH status, but our results suggest that astrocytomas
with mutations in the IDH genes have lower CD63 levels
compared to wildtype astrocytomas. Further, Rorive et al.
found an association between patient survival and CD63
in glioblastomas, however, combining TIMP-4 and CD63
scores in the survival analysis showed that simultaneous
expression of TIMP-4 and CD63 was a stronger negative
prognostic factor compared to CD63 and TIMP-4 alone
[37]. In the present study, high mRNA levels of CD63
were found to be associated with shorter overall survival
Fig. 6 Double-immunofluorescence stainings of glioblastoma biopsies and spheroids. a-c Co-expression of TIMP-1 and CD63, d-f co-expression of TIMP-1 and
the tumor stem cell-related marker CD133, and g-i co-expression of TIMP-1 and the tumor stem cell-related marker Sox2 in glioblastoma biopsies (a, d, g),
cultured organotypic primary spheroids (b, e, h) and U87MG cell line-derived spheroids (c, f, i). TIMP-1/CD63 co-expression was detected in the
biopsies (a) and spheroids (b, c). Only some tumor cells co-expressed TIMP-1 and CD133 in the biopsies (d) and spheroids (e, f). TIMP-1/Sox2
co-expression was detected in some tumor cells in the biopsies (g) and in the primary spheroids (h), whereas no Sox2 expression was detected in
the U87MG cell line derived spheroids (i). Scale bar: 30 μm
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using the TCGA dataset, but the association was not sig-
nificant in the protein data. Also, CD63 expression did
not affect the prognostic potential of TIMP-1 suggest-
ing that TIMP-1 is a more valuable prognostic marker
in glioblastomas compared to CD63 alone or in com-
bination with CD63. The discrepancy between our re-
sults and the results by Rorive et al. could be
explained by the number of patients included in the
studies as Rorive et al. had 265 glioblastomas in their
cohort, while our study only included 74 making it
more difficult to detect a significant difference. The
contradicting results could also be attributed to differ-
ent staining protocols and scoring systems. In contrast
to Rorive et al., we performed immunohistochemistry
on whole tissue sections as expression of several
markers may be under- or overestimated in tissue
microarrays due to the heterogeneity of gliomas.
Furthermore, TIMP-4 was only associated with prog-
nosis when co-expressed with CD63 [37]; in contrast,
we found that low TIMP-1 levels correlated with
Fig. 7 Differential expression analysis. a Volcano plot illustrating that 50 genes (red dots) were significantly upregulated above the 1.50-fold
threshold, and that 32 genes (red dots) were significantly downregulated below the 1.50-fold threshold. b-c The up- and downregulated genes
were hierarchically classified to biological processes using the Gene Ontology (GO) term enrichment analysis
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longer survival [14], and this finding was validated in
the present study using TCGA data. Altogether, these
results suggest that TIMP-1 is a stronger prognostica-
tor in glioblastoma patients compared to CD63 and
TIMP-4.
Recently, Kase et al. reported that a high number of
CD63+ immune cells was associated with improved
overall survival in glioblastoma patients [38]. In our
study, we did not score CD63 expression in immune
cells, but only in tumor cells and blood vessels. To
address the possible expression of CD63 by immune
cells, we performed double-immunofluorescence with
CD63 and Iba1. We found that up to approx. 40% of
the CD63+ cells co-expressed Iba1. To investigate the
impact of Iba1 on the prognostic value of CD63, we
used TCGA data and stratified patients based on the
mRNA levels of CD63 and Iba1; Iba1 did not appear
to influence CD63 substantially regarding patient sur-
vival. However, to fully elucidate the prognostic value
of CD63+ immune cells and CD63+ tumor cells, add-
itional prognostic studies should be performed e.g. by
confocal double-immunofluorescence analysis. Overall,
these conflicting results suggest that the specific cell
type expressing CD63 may be important regarding
prognosis.
In general, a weak CD63 expression was detected
in a few putative invading tumor cells. This is in line
with findings by Rorive et al. [37] and Wei et al.
[64], as CD63 expression levels were found to be
significantly higher in the tumor core compared to
the tumor margin and periphery suggesting that
CD63 mainly exerts its function in the bulk tumor.
Whether CD63 plays a role in glioblastoma invasion
needs further investigation. However, decreased
levels of CD63 were found to enhance tumor motil-
ity and invasion in melanoma cell lines [29, 31]. In
contrast, CD63 over-expression was reported to pro-
mote motility and frequency of metastases in a hu-
man uterine cervical cancer cell line [63], and CD63
knockdown was reported to increase invasion in
vitro in esophageal carcinoma [65].
Using double-immunofluorescence, we showed that
TIMP-1 and CD63 were co-expressed in some glioblast-
oma cells. Furthermore, the proximity ligation assay in-
dicated that TIMP-1 and CD63 were located within a
molecular distance suggestive of molecular interaction.
This possible protein-protein interaction could have im-
portance for the potential role of TIMP-1 in chemo-
resistance [9–13]. Jung et al. identified CD63 as a pos-
sible TIMP-1 interacting protein, and over-expression of
TIMP-1 in MCF10A cells resulted in inhibition of
caspase-mediated apoptosis, while down-regulation of
CD63 reversed the cellular protection mediated by
TIMP-1 suggesting an important role for the TIMP-1/
CD63 interaction in caspase-mediated apoptosis [28].
Whether this TIMP-1/CD63 interaction is present in
glioblastomas is not known, however, our results suggest
TIMP-1 and CD63 to be located in close molecular
proximity, but additional investigations needs to be per-
formed to elucidate possible biological roles of the
TIMP-1/CD63 interaction in glioblastoma. However, Lee
et al. found that TIMP-1 was a chemoattractant mol-
ecule enhancing the migration of neural stem cells to-
wards glioma cells in vitro and showed that the
migration was dependent on the expression of CD63 on
the neural stem cells, overall suggesting an interaction of
TIMP-1 and CD63 [41].
In the present study, we included spheroids to eluci-
date whether the co-expression of TIMP-1 and CD63,
CD133 or Sox2 were preserved in cultured tissue and
U87MG cell line-derived spheroids to determine if the
spheroid models could be used in future studies investi-
gating the role of TIMP-1 and CD63 in chemo-
resistance. We found preserved expression of TIMP-1
and CD63, CD133 or Sox2 in the biopsies, and to some
extent co-expression between the four proteins, suggest-
ing that preclinical spheroid models can be used to de-
termine the influence on chemo-resistance, also in
relation to tumor stem-like cells which have been sug-
gested to play an important role in resistance to anti-
cancer treatment [2, 66–68]. Whether tumor stem-like
cells in glioblastomas express CD63 has not been inves-
tigated directly in the present study as CD63 was
expressed by virtually all tumor cells in the glioblast-
omas. Interestingly, we observed an increased density of
CD63+ cells around blood vessels – similar to what has
been reported for CD133+ tumor cells being localized in
so-called perivascular niches [44].
Using the TCGA dataset, glioblastomas with the high-
est CD63 levels had a significant upregulation and down-
regulation of several genes compared to glioblastomas
with the lowest levels. Among the differentially downreg-
ulated genes were DLL-3, DCX, and LPPR1. DLL-3 is as-
sociated with the proneural subtype of glioblastomas
which is considered to be the least malignant and most
treatment-sensitive of the molecular glioblastoma sub-
types [69, 70]. LPPR1 is a member of the plasticity-
related gene family influencing neuronal morphology
[71, 72], but its potential function in gliomas is so far un-
known. DCX was reported to inhibit glioma invasion
in vitro [73] and reduce tumor volume in vivo [74] pos-
sibly by inducing apoptosis in tumor stem-like cells [75],
overall indicating that DCX is a tumor suppressor. GO
enrichment analysis of downregulated genes showed cat-
egories such as nervous system development and neuro-
genesis among the most enriched terms, thus consistent
with the characteristics of the proneural glioblastoma
subtype. Among the differentially upregulated genes
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were TIMP-1 as well as CHI3L1, PDPN, FAPB7, EMP3,
PTX3, and POSTN. High levels of CHI3L1 and EMP3
[76] as well as FAPB7 [77, 78] and POSTN [79, 80] were
reported as negative prognostic biomarkers in glioma.
PTX3 [81], FAPB7 [77, 78], POSTN [79], and PDPN [82]
are associated with increased glioma invasion, and both
PDPN and CHI3L1 reportedly contribute to radio-
resistance in glioblastoma [70, 83]. The upregulated genes
were found to be especially involved in regulation of cell
survival and cellular movement. CD63 is commonly used
as a molecular marker of exosomes [32, 33, 35]; exosomes
can provide an efficient and specific transfer of molecular
signals between cells also in cancer, and components of
both POSTN [84] and PDPN [85] are carried by exosomes
along with other factors that facilitate angiogenesis, im-
mune suppression, and oncogenesis [86]. In summary,
these data indicate that CD63 is differentially over-
expressed with molecules related to tumor aggressiveness
and resistance and may thus contribute to a pro-
tumorigenic microenvironment. The presence of CD63 in
exosomes and exosomes in general could be used in the
clinical setting as exosomes are carried in blood and shed
into biological fluids, where it may have a potential as a
diagnostic, predictive, or therapeutic tool [86].
Conclusions
In conclusion, we found an increased expression of CD63
in glioblastomas as well as a weak correlation between
CD63 and TIMP-1. However, the CD63 expression was not
significantly correlated with prognosis alone or in combin-
ation with TIMP-1 at a protein level, but high levels tended
to correlate with shorter overall survival. Interestingly,
TIMP-1 and CD63 appeared to be located in close molecu-
lar proximity suggesting TIMP-1/CD63 interaction. The ex-
pression and co-localization was preserved in spheroids
suggesting that spheroid models can be used in future stud-
ies investigating the possible biological role of the TIMP-1/
CD63 interaction in chemo-resistance.
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